Page 125 - Read Online

Zanetto et al. Hepatoma Res 2018;4:70 I http://dx.doi.org/10.20517/2394-5079.2018.102 Page 15 of 16

(STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54.
55. Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 2016;65:861-
2.
56. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack
of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol
2016;65:734-40.
57. Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, et al. Is the risk of neoplastic recurrence increased after prescribing
direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol 2017;66:236-7.
58. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients
affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.
59. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, et al. Hepatocellular carcinoma recurrence in patients with curative resection or
ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017;45:160-8.
60. Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, et al. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a
European multicentre study. J Hepatol 2017;67:876-8.
61. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a
systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
62. Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, et al. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma
following direct-acting antiviral therapy. Aliment Pharmacol Ther 2018;48:127-37.
63. Nakao Y, Hashimoto S, Abiru S, Komori A, Yamasaki K, et al. Rapidly growing, moderately differentiated HCC: a clinicopathological
characteristic of HCC occurrence after IFN-free DAA therapy? J Hepatol 2017; doi: 10.1016/j.jhep.2017.11.011.
64. Renzulli M, Buonfiglioli F, Conti F, Brocchi S, Serio I, et al. Imaging features of microvascular invasion in hepatocellular carcinoma
developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol 2018;28:506-13.
65. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk
of liver and non-liver complications. Gastroenterology 2017;152:142-56.
66. Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, et al. Dropout rate from the liver transplant waiting list because of hepatocellular
carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl 2017;23:1103-12.
67. Werner JM, Adenugba A, Protzer U. Immune reconstitution after HCV clearance with direct antiviral agents: potential consequences for
patients with HCC? Transplantation 2017;101:904-9.
68. Claassen MA, Janssen HL, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol 2013;3:461-7.
69. Burchill MA, Golden-Mason L, Wind-Rotolo M, Rosen HR. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-
infected patients receiving direct-acting antivirals. J Viral Hepat 2015;22:983-91.
70. Yoong KF, McNab G, Hübscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating
lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998;160:3978-88.
71. Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, et al. Immunodominance and functional alterations of tumor-associated antigen-
specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 2014;59:1415-26.
72. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic
infiltration. Hepatology 1998;27:407-14.
73. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
74. Debes JD, Janssen HL, Boonstra A. Hepatitis C treatment and liver cancer recurrence: cause for concern? Lancet Gastroenterol Hepatol
2017;2:78-80.
75. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 2016;16:112-23.
76. Körner C, Riesner K, Krämer B, Eisenhardt M, Glässner A, et al. TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated
with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer 2012;12:85.
77. Spaan M, van Oord G, Kreefft K, Hou J, Hansen BE, et al. Immunological analysis during interferon-free therapy for chronic hepatitis C
virus infection reveals modulation of the natural killer cell compartment. J Infect Dis 2016;213:216-23.
78. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, et al. Successful interferon-free therapy of chronic hepatitis C virus infection
normalizes natural killer cell function. Gastroenterology 2015;149:190-200.
79. Waring JF, Dumas EO, Abel S, Coakley E, Cohen DE, et al. Serum miR-122 may serve as a biomarker for response to direct acting
antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. J Viral Hepat 2016;23:96-104.
80. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis
of hepatocellular carcinoma. Hepatology 2009;49:1571-82.
81. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism
of genetic exchange between cells. Nat Cell Biol 2007;9:654-9.
82. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance
estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004;64:5245-50.
83. Waidmann O, Bihrer V, Kronenberger B, Zeuzem S, Piiper A, et al. Pretreatment serum microRNA-122 is not predictive for treatment
response in chronic hepatitis C virus infection. Dig Liver Dis 2012;44:438-41.
84. Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, et al. DAAs rapidly reduce inflammation but increase serum VEGF Level: a
rationale for tumor risk during anti-hcv treatment. PLoS One 2016;11:e0167934.
85. Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer
after hepatitis C virus direct-acting antivirals. Hepatology 2018;68:1010-24.
86. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, et al. Levels of cytokines in serum associate